Mpox vaccine safety surveillance conducted by AusVaxSafety was completed on 17 April 2023. Data on this page will no longer be updated. Safety data collected from more than 15,000 JYNNEOS mpox vaccine recipients identified no safety issues in either administration method, intradermal and subcutaneous.

The Therapeutic Goods Administration (TGA) continues to monitor the safety of mpox vaccines in Australia.

Data on this page show the responses of all individuals who received a JYNNEOS mpox (monkeypox) vaccine administered via subcutaneous* injection and completed an AusVaxSafety survey sent on day 7 after vaccination. These data provide you with a profile of what to expect in the days following your mpox vaccination and can assist when planning for your mpox vaccination.


*Subcutaneous vaccine administration uses a short needle to inject a 0.5 mL dose of the JYNNEOS mpox vaccine into the fatty tissue layer (subcutaneous layer) located between the skin and the muscle.

AusVaxSafety's active vaccine safety surveillance system complements the Therapeutic Goods Administration's (TGA) safety surveillance activities. Find out more about how the TGA monitors the safety of vaccines and how you can report side effects on the TGA website.

Links to further information on mpox vaccines are available below: 

AusVaxSafety will continue to closely monitor the safety data of mpox vaccines in use in Australia in conjunction with the TGA, the Department of Health and Aged Care and state and territory health departments.

Last updated April 2023